Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2021 09:15 ET | Source: Newscope Capital Corporation

World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor

TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc....
March 02, 2021 07:00 ET | Source: Newscope Capital Corporation

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease

TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
March 01, 2021 07:57 ET | Source: Newscope Capital Corporation

Newscope Announces DTC Eligibility of Its Common Shares in the United States

TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc....
February 23, 2021 07:00 ET | Source: Newscope Capital Corporation

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
February 17, 2021 09:02 ET | Source: Newscope Capital Corporation

PharmaTher Announces Sale of Psilocybin Program

TORONTO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher” or the “Company”), is a...
February 04, 2021 08:00 ET | Source: Newscope Capital Corporation

PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease

TORONTO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
February 01, 2021 07:59 ET | Source: Newscope Capital Corporation

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

TORONTO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
January 19, 2021 07:34 ET | Source: Newscope Capital Corporation

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders

TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
January 13, 2021 08:30 ET | Source: Newscope Capital Corporation

PharmaTher Approved to Trade on the OTCQB Venture Market

TORONTO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF) (the "Company"), who through its wholly-owned subsidiary, PharmaTher Inc., is a specialty life...
December 30, 2020 08:00 ET | Source: Newscope Capital Corporation

PharmaTher Announces Application for OTCQB Listing

TORONTO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) (the “Company”), who through its wholly owned subsidiary, PharmaTher Inc., is a specialty life...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right